DADC
SRNE

D.A. Davidson & Co’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

D.A. Davidson & Co’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,000
Closed -$109K – 1185
2020
Q4 		$109K Hold
16,000
– – ﹤0.01% 990
2020
Q3 		$178K Buy
16,000
+5,500
+52% +$50.3K ﹤0.01% 895
2020
Q2 		$66K Buy
+10,500
New +$40.2K ﹤0.01% 915

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

D.A. Davidson & Co's SRNE Position: Q1 2021 in Review

D.A. Davidson & Co sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2021, closing a stake of 16,000 shares — an estimated $109K sold.

D.A. Davidson & Co first reported a position in SRNE in Q2 2020 and held it in 3 quarters. The position peaked at $178K in Q3 2020. 231 funds tracked by Wall St. Rank hold SRNE as of Q1 2021.

  • D.A. Davidson & Co reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • D.A. Davidson & Co sold 16,000 Sorrento Therapeutics, Inc. shares in Q1 2021, an estimated $109K.
  • D.A. Davidson & Co first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
  • D.A. Davidson & Co's Sorrento Therapeutics, Inc. position peaked at $178K in Q3 2020.
  • 231 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2021.

Based on D.A. Davidson & Co's 13F filing for Q1 2021, filed 7 May 2021.